Skip to contents

HTA Plaque Psoriasis

Source: R/data.R
hta_psoriasis.Rd

Data frame containing the results of 16 trials comparing 8 treatments for moderate-to-severe plaque psoriasis from an HTA report (Woolacott et al. 2006) , analysed in TSD2 (Dias et al. 2011) . Outcomes are success/failure to achieve 50%, 75%, or 90% reduction in symptoms on the Psoriasis Area and Severity Index (PASI) scale. Some studies report all three ordered outcomes, others only one or two. The latter are coded as missing values (see details).

Usage

hta_psoriasis

Format

A data frame with 36 rows and 9 variables:

studyn

numeric study ID

studyc

study name

year

year of publication

trtn

numeric treatment code

trtc

treatment name

sample_size

sample size in each arm

PASI50, PASI75, PASI90

ordered multinomial outcome counts (exclusive, see details)

Details

Outcome counts are "exclusive"; that is, for a study reporting all outcomes, the counts represent the categories 50 < PASI < 75, 75 < PASI < 90, and 90 < PASI < 100, and are named by the lower end of the interval. (As opposed to "inclusive" counts, which would represent the overlapping categories PASI > 50, PASI > 70, and PASI > 90.) The count for the fourth category (the lowest), 0 < PASI < 50, is equal to sample_size - PASI50 - PASI75 - PASI90.

Missing values are used where studies only report a subset of the outcomes. For a study reporting only two outcomes, say 50 and 75, the counts represent 50 < PASI < 75 and 75 < PASI < 100. For a study reporting only one outcome, say PASI 75, the count represents 75 < PASI < 100.

References

Dias S, Welton NJ, Sutton AJ, Ades AE (2011). “NICE DSU Technical Support Document 2: A generalised linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials.” National Institute for Health and Care Excellence. https://www.sheffield.ac.uk/nice-dsu.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R (2006). “Etanercept and efalizumab for the treatment of psoriasis: a systematic review.” Health Technology Assessment, 10(46). doi:10.3310/hta10460 .